Agile Therapeutics (NASDAQ:AGRX) Receives New Coverage from Analysts at StockNews.com

StockNews.com began coverage on shares of Agile Therapeutics (NASDAQ:AGRX) in a report issued on Sunday. The firm issued a sell rating on the specialty pharmaceutical company’s stock.

Separately, Maxim Group reiterated a hold rating on shares of Agile Therapeutics in a report on Monday, March 18th.

Agile Therapeutics Price Performance

NASDAQ AGRX opened at $0.32 on Friday. The firm has a market capitalization of $2.17 million, a P/E ratio of -0.09 and a beta of 1.23. Agile Therapeutics has a 1-year low of $0.20 and a 1-year high of $3.40. The business’s 50-day simple moving average is $0.38 and its 200-day simple moving average is $0.93.

Agile Therapeutics (NASDAQ:AGRX) last released its quarterly earnings results on Wednesday, May 15th. The specialty pharmaceutical company reported ($0.63) EPS for the quarter. The company had revenue of $5.72 million during the quarter.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Agile Therapeutics stock. Armistice Capital LLC lifted its stake in Agile Therapeutics, Inc. (NASDAQ:AGRX) by 10.2% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 108,000 shares of the specialty pharmaceutical company’s stock after purchasing an additional 10,000 shares during the quarter. Armistice Capital LLC owned 3.65% of Agile Therapeutics worth $211,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 10.92% of the company’s stock.

About Agile Therapeutics

Agile Therapeutics, Inc, a women's healthcare company, engages in the research, development, and commercialization of prescription contraceptive products for women in the United States. It offers Twirla, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.